Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform

Summary Mesenchymal stem cells (MSCs) are one of the most easily accessible stem cells that can be obtained from various human tissues. They have raised considerable interests for their potential applications in tissue repair, anti‐cancer therapy, and inflammation suppression. Stem cell‐based therap...

Full description

Saved in:
Bibliographic Details
Published inStem cells translational medicine Vol. 8; no. 9; pp. 880 - 886
Main Authors Baek, Gyuhyeon, Choi, Hojun, Kim, Youngeun, Lee, Hai‐Chon, Choi, Chulhee
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.09.2019
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Mesenchymal stem cells (MSCs) are one of the most easily accessible stem cells that can be obtained from various human tissues. They have raised considerable interests for their potential applications in tissue repair, anti‐cancer therapy, and inflammation suppression. Stem cell‐based therapy was first used to treat muscular dystrophies and has been studied intensively for its efficacy in various disease models, including myocardial infarction, kidney injuries, liver injuries, and cancers. In this review, we summarized the potential mechanisms underlying MSC‐derived EVs therapy as a drug delivery platform. Additionally, based on currently published data, we predicted a potential therapeutic role of cargo proteins shuttled by EVs from MSCs. These data may support the therapeutic strategy of using the MSC‐derived EVs to accelerate this strategy from bench to bedside. Stem Cells Translational Medicine 2019;8:880&886
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Contributed equally.
ISSN:2157-6564
2157-6580
DOI:10.1002/sctm.18-0226